IMMUNOPHENOTYPIC DESCRIPTION OF PATIENTS WITH A MYELODYSPLASTIC SYNDROME AND 2 SPECIFIC CYTOGENETICS ABNORMALITIES: DELETION OF 5Q AND TRISOMY 8

被引：0
|
作者：
Subira, M. [1 ]
Font, P. [2 ]
Arranz, E. [3 ]
Serrano, C. [1 ]
Gonzalo, R. [1 ]
Castanon, S. [1 ]
Mata, R. [1 ]
Soto, C. [1 ]
Olaso, E. [4 ]
Roman, A. [1 ]
Lamas, P. L. [1 ]
机构：
[1] Fdn Jimenez Diaz, E-28040 Madrid, Spain
[2] Clin Moncloa, Madrid, Spain
[3] Gemolab Lab, Madrid, Spain
[4] Clin Santa Elena, Madrid, Spain
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0719
引用
收藏
页码：289 / 289
页数：1
相关论文
共 50 条
  • [41] 5q duplication and 13q deletion in a patient with Fanconi anemia associated with Myelodysplastic syndrome
    Bennour, H. Sennana
    Omri, H. E. L.
    Khelif, A.
    Saad, A.
    CHROMOSOME RESEARCH, 2007, 15 : 218 - 219
  • [42] SURVIVAL OF PATIENTS WITH DE NOVO MYELODYSPLASTIC SYNDROME AND del(5q)
    Gritsaev, S. V.
    Martynkevich, I. S.
    Petrova, E. V.
    Martynenko, L. S.
    Kostroma, I. I.
    Ivanova, M. P.
    Tsybakova, N. Yu.
    Kozlovskaya, M. A.
    Sergeyev, A. N.
    Tiranova, S. A.
    Potikhonova, N. A.
    Abdulkadyrov, K. M.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2013, 58 (01): : 3 - 9
  • [43] Short Telomeres Before Lenalidomide Treatment Predict Leukemic Progression In Patients with Myelodysplastic Syndrome and Deletion 5q
    Gohring, Gudrun
    Lange, Kathrin
    Hofmann, Winfried
    Nielsen, Kirsten Vang
    Hellstrom-Lindberg, Eva
    Roy, Lydia
    Morgan, Michael
    Kreipe, Hans
    Buesche, Guntram
    Giagounidis, Aristoteles
    Schlegelberger, Brigitte
    BLOOD, 2010, 116 (21) : 18 - 18
  • [44] Adjusted dose lenalidomide is safe and effective in patients with deletion (5q) myelodysplastic syndrome and severe renal impairment
    Knop, Stefan
    Einsele, Hermann
    Bargou, Ralf
    Cosgrove, Denise
    List, Alan
    LEUKEMIA & LYMPHOMA, 2008, 49 (02) : 346 - 349
  • [45] Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide
    G Göhring
    K Lange
    W Hofmann
    K V Nielsen
    E Hellström-Lindberg
    L Roy
    M Morgan
    H Kreipe
    G Büsche
    A Giagounidis
    B Schlegelberger
    Leukemia, 2012, 26 : 356 - 358
  • [46] Response to lenalidomide in patients with myelodysplastic syndrome with deletion 5q: clinical and cytogenetic analysis of a single centre series
    Coutinho, Rita
    Costa, Dolors
    Carrio, Ana
    Munoz, Concha
    Vidal, Ana
    Belkaid, Mohammed
    Campo, Elias
    Nomdedeu, Benet
    ANNALS OF HEMATOLOGY, 2010, 89 (10) : 1069 - 1070
  • [47] Mechanisms of Resistance to Lenalidomide in Del(5q) Myelodysplastic Syndrome Patients
    Martinez-Hoyer, Sergio
    Docking, Rod
    Chan, Simon
    Jadersten, Martin
    Parker, Jeremy
    Karsan, Aly
    BLOOD, 2015, 126 (23)
  • [48] CHARACTERIZATION OF THE TRANSCRIPTIONAL ALTERATIONS OF PATIENTS WITH DEL(5Q) MYELODYSPLASTIC SYNDROME
    Berastegui Zufiaurre, N.
    Serrano, G.
    Diaz Mazkiaran, A.
    Huerga, S.
    Garcia-Olloqui, P.
    Ainciburu, M.
    Alfonso, A.
    Vilas-Zornoza, A.
    San Martin, P.
    Lamo De Espinosa, J. M.
    Acha, P.
    Jimenez Solas, T.
    Molero, A.
    Montoro, M. J.
    Campelo, M.
    Valcarcel, D.
    Sole, F.
    Ochoa, I.
    Hernaez, M.
    Ezponda, T.
    Prosper, F.
    LEUKEMIA RESEARCH, 2023, 128
  • [49] Analysis of the efficacy of lenalidomide in patients with intermediate-1 risk myelodysplastic syndrome without 5q deletion
    Yang, Yan
    Gao, Sujun
    Fan, Hongqiong
    Lin, Hai
    Li, Wei
    Wang, Juan
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2013, 6 (03) : 803 - 807
  • [50] Response to lenalidomide in patients with myelodysplastic syndrome with deletion 5q: clinical and cytogenetic analysis of a single centre series
    Rita Coutinho
    Dolors Costa
    Ana Carrió
    Concha Muñoz
    Ana Vidal
    Mohammed Belkaid
    Elias Campo
    Benet Nomdedeu
    Annals of Hematology, 2010, 89 : 1069 - 1070
12345